Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03699657 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Dual and Single Switching Monopolar RFA Using Octopus Electrodes for Treatment of HCC

Start date: December 15, 2014
Phase: N/A
Study type: Interventional

This study was conducted to prospectively compare the efficacy, safety and mid-term outcomes of dual-switching monopolar (DSM) radiofrequency ablation (RFA) with those of conventional single-switching monopolar (SSM) RFA in the treatment of hepatocellular carcinoma (HCC).

NCT ID: NCT03212625 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction

Start date: January 28, 2016
Phase: Phase 4
Study type: Interventional

Many investigators have studied for prevention and care of Hand-Foot Skin Reaction(HFSR), and urea cream is typical representative. Recent study was performed prevention effect of urea cream for Hand-Foot Skin Reaction(HFSR) on 871 Chinese. But the study did not designed as placebo-control group and it had big defect in double-blinded. Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect of urea cream on Korean patient group.

NCT ID: NCT03158818 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Chronic Hepatitis B Virus Infection in Zambia

HUTCH
Start date: August 23, 2016
Phase:
Study type: Observational

Chronic hepatitis B virus infection is a common condition in Zambia. Among Zambian blood donors, up to 8% are chronically infected with HBV. Despite the burden, awareness of HBV is low in Zambia and the Ministry of Health is in early stages of development of guidelines for HBV screening, treatment, and prevention. The purpose of this clinical cohort study is to characterize the clinical features of chronic HBV infection at UTH and describe treatment and care outcomes. The investigators will enroll 500 adults and follow the cohort for up to 5 years to assess short and long-term viral, serologic, and liver outcomes such as cirrhosis and liver cancer.

NCT ID: NCT02960594 Active, not recruiting - Breast Cancer Clinical Trials

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

TRT-001
Start date: December 2014
Phase: Phase 1
Study type: Interventional

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.

NCT ID: NCT02882659 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Dendritic Killer Cell-based Immunotherapy for Solid Tumors

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC. The primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (AE). The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3+ CD8+ CD69+ IFN-gamma+ T cells, and the improvement of quality of life

NCT ID: NCT02854241 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance

Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate clinical feasibility of annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in high-risk group, in comparison with biannual ultrasonography.

NCT ID: NCT02828124 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Start date: August 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.

NCT ID: NCT02783261 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Prospective Post Y90 Liver Hypertrophy

Start date: June 2014
Phase: N/A
Study type: Observational

Patients undergoing Y90 radioembolization to will be followed prospectively with CT volumetry to determine post-Y90 rate of liver hypertrophy.

NCT ID: NCT02774187 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

Start date: May 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with sorafenib Alone in patients with hepatocellular carcinoma (HCC) with major portal venous tumor thrombus (PVTT).

NCT ID: NCT02759601 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)

CHR-2845
Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being carried out to assess the best dose of a new drug, called tefinostat, in treating liver cancer. Tefinostat is a new drug that blocks enzymes called histone deacetylases (pronounced dee-as-et-isle-azes). Cells need these enzymes to grow and divide. Blocking them may stop cancer growing. Drugs that block these enzymes are called histone deacetylase inhibitors or 'HDAC inhibitors'. Tefinostat has never been given to patients with liver cancer before so it isn't known which dose is best at treating liver cancer. To find this out the study will be testing one dose and if that is safe, then test a higher dose and so on. The aim of this study is to find the best dose of tefinostat without causing side effects. The study will be looking closely at any side effects patients might experience from this treatment.